Amazon Great Indian Festival 2020 - Electronics
Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Amazon Great Indian Festival 2020 - Electronics
Research

| More

Natco Pharma - Natco to launch first generic Revlimid - ICICI Securities

Posted On: 2020-09-18 01:46:54


Natco Pharma (Natco) would be the first company to launch Revlimid (lenalidomide) in Mar'22 as Dr Reddy's (DRL) settlement with Celgene over its patent clears the path for Natco. DRL would launch sometime after Natco (we assume 6 months) and would have market share restrictions lower than Natco in our view. Till date, three companies (Natco, DRL and Alvogen) have settled the litigation with innovator and would launch during this exclusivity period (FY23-FY26). We expect Natco to generate total revenue and PAT of US$1.3bn and US$900mn during the shared exclusivity period over FY23-FY26. This would imply an NPV of Rs302/share for Revlimid for Natco. Upgrade to BUY.

- Certainty emerges on Revlimid launch: After DRL's settlement with Celgene over Revlimid patent litigation, clarity has emerged on Natco's launch. Natco would now launch in Mar'22 and will have ~6months of head start before competitor's (DRL) launch. We also believe that Natco would have superior market share restrictions as compared to other players. As per Natco's settlement with Celgene, it can launch generic Revlimid in Mar'22 with mid-single digit market share constraint in first year which can gradually increase to ~33% in final year of exclusivity (FY26). Post Jan'26, there would not be any market share constraint.

- Value Revlimid opportunity at Rs302/share: The annual market size of this product is ~US$8bn. Teva is the marketing partner for Natco and we assume Natco's share in the opportunity to be around 35%. Considering the factor of market share constraint, we believe pricing pressure would not be significant. We value Revlimid opportunity for Natco at Rs302/share.

- Valuations and risks: We raise FY23 revenue/EPS estimates by 32.7/94.7% to factor in generic Revlimid sales. Considering certainty on Revlimid opportunity and 38.0% EPS CAGR over FY20-FY23E, we upgrade Natco to BUY from Add with a revised SoTP-based target price of Rs954/share (earlier: Rs875/share) including NPV of Rs302/share for Revlimid. Key downside risks: Delay in US launches and earlier-than-anticipated competition in Copaxone.

Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.773.75 as compared to the previous close of Rs. 775. The total number of shares traded during the day was 20686 in over 1464 trades.

The stock hit an intraday high of Rs. 789.9 and intraday low of 765.1. The net turnover during the day was Rs. 16115922.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com

Amazon Great Indian Festival 2020 - Mobiles


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Nestle India - 3QCY20 results - First Cut - YES SECURITIES

Crude Oil - Oct 23, 2020 - Reliance Securities

Maintain BUY on Ambuja Cements - Stellar show yet again; dividend bonanza announced - HDFC Securities

ADD on Bajaj Auto - Margin beat - HDFC Securities

Maintain REDUCE on Asian Paints - Standing tall - HDFC Securities

SBI cards - Q2FY21 - Angel Broking

Biocon - Q2FY21 - Angel Broking

Mphasis - Q2FY21 numbers - Angel Broking

L&T Finance Holdings - Q2FY21 - Angel Broking

HDFC AMC - Q2FY21 - Angel Broking

Bajaj Finserv (Not rated) - Q2 FY21 Conference Call Takeaways - YES Securities

Syngene International - Q2FY21 conference call takeaways - YES Securities

SBI Cards Q2FY21 Call Highlights - YES Securities

Sterlite Technologies (Q2FY21) - Conference call takeaways - YES Securities

Asian Paints Ltd - Q2FY21 Result Update - YES Securities

HDFC AMC - Q2FY21 Result Update - YES Securities

Alembic Pharma - Solid delivery continues; Top pick BUY TP Rs 1,180 - YES Securities

Sterlite Technologies - Q2FY21 First Cut - ICICI Securities

Tata Metaliks - Q2FY21 Company Update - ICICI Securities

Bajaj Auto - Q2FY21 First Cut - ICICI Securities

Bajaj Finserv - Q2FY21 Result Update - ICICI Securities

Asian Paints - Q2FY21 First Cut - ICICI Securities

Bharti Infratel - Q2FY21 - Angel Broking

Asian Paints - Q2FY21 - Angel Broking

Bajaj Auto - Q2FY21 numbers - Angel Broking

Maintain ADD on Bajaj Finance - Prudent provisioning hits profits - HDFC Securities

FDA warning letter to Aurobindo Pharma - Angel Broking

Chennai Petroleum - Q2FY221 Results - Angel Broking

Maintain ADD on Colgate Palmolive - Healthy domestic recovery; robust margin show - HDFC Securities

Maintain BUY on UltraTech Cement - Well-rounded performance - HDFC Securities

DB Corp - Q2FY21 Result Update - ICICI Securities

Bajaj Finance - Q2FY21 Result Update - ICICI Securities

Colgate-Palmolive (India) - Q2FY21 Result Update - ICICI Securities

UltraTech Cement - Q2FY21 Result Update - ICICI Securities

Larsen & Toubro Infotech - Q2FY21 Result Update - ICICI Securities

Sagar Cements - Q2FY21 First Cut - ICICI Securities

JK Tyre & Industries - Q2FY21 First Cut - ICICI Securities

Bajaj Finserv - Q2FY21 First Cut - ICICI Securities

UltraTech Q2FY21 - Retain ADD with TP of Rs 5,104 - YES Securities

Bajaj Finance - Q2FY21 - Result Update - YES Securities

Sagar Cements Q2FY21 - EBITDA at lifetime high; maintain TP of Rs 745 - YES Securities

JK Tyre - Q2FY2021 numbers - Angel Broking

Sagar Cements - Q2FY21 Results - Angel Broking

Bajaj Finance - Q2FY21 Results - Angel Broking

Bajaj Finance Q2FY21 - Retain ADD - 12m PT of Rs. 3,600 - YES SECURITIES

PNC Infratech - JV emerges L1 bidder - Angel Broking

GMM Pfaudler - Q2FY21 Results - Angel Broking

Rane Madras - Q2FY21 numbers - Angel Broking

Colgate-Palmolive - Q2FY21 Result - Angel Broking

Quant Pick - Tata Steel - ICICI Securities







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019